Drug manufacturers AstraZeneca and Sanofi have asked 340B administrative dispute resolution panels to pause covered entities’ ADR proceedings against them until all 340B-related federal court litigation is finished and until after the government finalizes its forthcoming new 340B ADR regulation.
The National Association of Community Health Centers (NACHC) is opposing any further delay of its ADR petitions against AstraZeneca and Sanofi. Ryan White Clinics for 340B Access (RWC-340B), which has brought ADR claims against AstraZeneca only, likewise is opposing that company’s requests for an indefinite stay.
Drug manufacturers AstraZeneca and Sanofi have asked 340B administrative dispute resolution panels to pause covered entities’ ADR proceedings against them until all 340B-related federal court litigation is finished and until after the government finalizes its forthcoming new 340B ADR regulation.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
